查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1136909

2022-2029 年全球代谢组学市场

Global Metabolomics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

代谢组学市场的增长受到研发支出增加、靶向治疗的广泛采用、技术进步、医疗和研发支出增加以及临床应用技术采用增加的推动。

研发费用增加有望推动市场增长

预计在预测期内，私营和政府组织对研发的资金不断增加将提振市场。例如，加拿大创新基金会的重大科学计划基金向代谢组学创新中心 (TMIC) 提供了 8,879,183 美元，向 Glyconet Integration Services (GIS) 提供了 1,064,968 美元，使这些中心成为糖组学和代谢组学等领域的先驱。我们支持继续的综合研究。

此外，市场参与者正在采用收购、合作和产品发布等市场策略。例如，2020 年，丹纳赫公司收购了 GE Healthcare 的生命科学业务。同样在 2020 年，安捷伦和赛默飞世尔扩展了他们的协议，以增强赛默飞世尔分析系统与安捷伦 OpenLAb 色谱数据系统之间的兼容性。

2020 年，沃特世公司宣布在剑桥肯德尔广场中心开设其研究机构 Immerse Cambridge。凭藉区域性战略合作场所 Immerse Cambridge，沃特世将与学术界和研究机构合作，加速下一个科学发现。 2020年，我们收购了日立高新技术的剩余股份，使其成为子公司。该子公司将负责测量和分析设备的製造以及芯片製造设备和工业材料和系统的开发。

数据复杂性阻碍市场增长

然而，由于小分子代谢物的化学多样性，不可能用单一的分析方法分析整个代谢组。因此，对于物理存储、准确和彻底的分析和可视化的合适软件/数据库的需求越来越大。此外，获得的数据也变得越来越复杂。因此，生命科学研究过程中产生的数据的复杂性以及与其处理相关的挑战预计将限制代谢组学市场的发展。

COVID-19 影响分析

COVID-19 的出现对全球代谢组学市场产生了相当大的影响。根据 2022 年 1 月发表在《科学报告》上的一篇文章，虽然一些代谢组学研究使用了核磁共振 (NMR)，但基于质谱 (MS) 的代谢组学在 COVID-19 疾病中具有前景。它是识别候选者的首选方法诊断生物标誌物。代谢组学已被用于解决与 COVID-19 疾病相关的各种主题。例如，代谢组学显示恢復期非重症 COVID-19 患者的性别特异性代谢变化，表明血浆代谢的主要变化是男性的脂肪酸以及男性和女性的甘油磷酸胆碱和碳水化合物。如代谢组学所示，肺功能受损的 COVID-19 倖存者的血浆代谢物谱可能与健康供体和肺功能正常的患者区分开来。

此外，在大流行期间，主要参与者都在从事研究活动。例如，2020年12月，布鲁克公司开发的FluoroType SARS-CoV-2/Flu/RSV Winter 4-plex PCR panel对SARS-CoV-2病毒、流感病毒A和B、呼吸道同时检测网状病毒（RSV）具有高敏感性。

2020 年 7 月，布鲁克公司宣布“FluoroType SARS-CoV-2 plus 下一代 6-plex PCR 检测”上市销售。

全球代谢组学市场报告由大约 60 多个市场数据表、55 多个数字和 200 多个（大约）页组成。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 技术进步
      • 对代谢组学治疗的需求不断扩大
    • 约束因素
      • 代谢组学设备成本高
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品/服务分类

  • 分离技术
    • 色谱法
    • 液相色谱
    • 气相色谱
    • 毛细管电泳
  • 检测技术
    • 核磁共振波谱
    • 质谱
    • 其他
  • 生物信息学工具和服务

第 8 章. 按应用程序

  • 营养基因组学
  • 生物标誌物和药物发现
  • 毒理学测试
  • 个性化医疗
  • 其他

第 9 章适应症

  • 癌症
  • 神经系统疾病
  • 先天性代谢紊乱
  • 心血管疾病
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 12 章公司简介

  • Thermo Fisher Scientific Inc.
    • 公司简介
    • 治疗类型组合和描述
    • 主要亮点
    • 财务摘要
  • Bio-Rad Laboratories
  • Agilent Technologies Inc.
  • Danaher Corporation
  • Waters Corporation
  • Bruker Corporation
  • Human Metabolome Technologies, Inc.
  • Metabolon Inc.
  • LECO Corporation
  • Shimadzu Corporation

第 13 章全球代谢组学市场-DataM

简介目录
Product Code: DMMD448

Market Overview

Metabolomics Market was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 11.2% during the forecast period (2022-2029).

In metabolomics, biological metabolites are identified and quantified using sophisticated analytical techniques, and information is extracted and interpreted using statistical and multivariate approaches. LC-MS/MS, GC-MS, and/or NMR are some of the complimentary analytical techniques used in metabolomics to identify and quantify as many known and unidentified metabolites as possible.

Market Dynamics

The metabolomics market growth is driven by the rising funding in research and development, rising adoption of targeted therapies, technological advamcement, increasing healthcare and R&D expenditure, rise in adoption of technology for clinical applications.

The rising funding for reserch and development is expected to drive the market growth

The rising funding for research and development from private and government organizations is expected to boost the market over the forecast period. For instance, the Canadian Foundation for Innovation's Major Science Initiatives Fund has provided $8,879,183 to The Metabolomics Innovation Centre (TMIC) and $10,684,968 to GlycoNet Integrated Services (GIS), helping these centers to continue their pioneering research, including glycomics and metabolomics.

In addition, the market players are adopting market strategies, including acquisition, collaboration and product launches. For instance, in 2020, Danaher Corporation acquired GE Healthcare's Life Sciences business. Also, In 2020, Agilent and Thermo Fisher extended their agreement to enhance the compatibility of Thermo Fisher's analytical systems with Agilent's OpenLAb Chromatography Data System.

In 2020, Waters Corporation announced the opening of Immerse Cambridge, a research facility in the center of Kendall Square in Cambridge. The community's strategic, collaborative venue, Immerse Cambridge, will allow Waters to work with academia and research to accelerate the next round of scientific discoveries. Also, in 2020, Hitachi acquired the remaining shares of Hitachi High-Technologies billion and made it is subsidiary. This subsidiary will be responsible for manufacturing measuring and analytical equipment, along with developing chipmaking equipment and industrial materials and systems.

The complexity of the data will hamper the growth of the market

However, no one analytical method can be used to analyze the full metabolome due to the chemical diversity of small molecule metabolites. Therefore, there is an increased demand for physical storage, accurate and thorough analysis, and appropriate software/databases for visualization. The resulting data is also more complicated. Therefore, it is anticipated that the complexity of the data produced during life science research and the challenges associated with handling it will restrain the development of the metabolomics market.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global metabolomics market. As per the article published in Scientific Reports in January 2022, While some metabolomics studies have used nuclear magnetic resonance (NMR), mass spectrometry (MS)-based metabolomics has been the method of choice for identifying prospective diagnostic biomarker candidates in COVID-19 disease. Metabolomics has been used to address various topics related to COVID-19 disease. For example, metabolomics has shown sex-specific metabolic shifts in non-severe COVID-19 patients during recovery, demonstrating that the major plasma metabolic changes were fatty acids in men and glycerophosphocholines and carbohydrates in men and women. As demonstrated by metabolomics, plasma metabolite profiles of COVID-19 survivors with impaired pulmonary function may be distinguished from those of healthy donors or those with normal pulmonary function.

In addition, the key players are engaged in research activities during the pandemic. For instance, in December 2020, The FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel, developed by Bruker Corporation, allows for the sensitive and simultaneous detection of the SARS-CoV-2 virus, influenza viruses A and B, as well as the respiratory syncytial virus (RSV)

Also, in July 2020, The FluoroType SARS-CoV-2 plus next-generation 6-plex PCR assay was introduced by Bruker Corporation to precisely identify the SARS-CoV-2 virus, which is responsible for the respiratory and systemic illness COVID-19.

Segment Analysis

The separation technique segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The separation technique segment is expected to boost the market throughout the forecast. As per the article published in Novel Approaches in Drug Designing & Development in August 2021, the analytical technique of liquid chromatography is used to isolate the target analyte from the mixture. To effectively separate molecules of interest, liquid chromatography uses a liquid as the mobile phase and a solid as the stationary phase. Mass spectroscopy is performed to determine the molecular mass of the sample of interest. By measuring the sample ion's mass to charge ratio, the molecule's mass is ascertained. Due to its selectivity, low sample volume requirements, sensitivity, and speed, the combination of liquid chromatography and mass spectrometry (LC-MS) is a potent instrument with several applications. LC is now compatible with MS due to creative and fruitful research over the past few years on constructing a potential interface link between the two. In the preclinical development stage, LC-MS detects impurities, degradants, and metabolites. In addition, the use of LC-MS/MS for protein quantification has attracted much attention. It is employed in the detection of biomarkers.

Geographical Analysis

North America region holds the largest market share of the global Metabolomics market

North America dominates the metabolomics market and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to government initiatives, growth and development research activities in metabolomics, and an increase in the adoption of metabolomics in precision medicine.

The primary aim of the Metabolomics Association of North America (MANA) is to advance the field of metabolomics, particularly in North America; to give North American researchers in metabolomics sciences and related fields the chance to network; to facilitate connections between academia and industry; to provide venues for the presentation of research findings and for workshops, and to encourage the publication of metabolomics research.

In addition, in April 2020, Gilead Sciences, Inc., and Second Genome, entered into a four-year strategic collaboration to find potential new targets and drug candidates for the treatment of inflammatory bowel disease as well as to identify biomarkers linked to clinical response in up to five of Gilead's pipeline compounds for the treatment of fibrosis, inflammation, and other diseases (IBD).

Competitive Landscape

The metabolomics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Agilent Technologies Inc., Danaher Corporation, Waters Corporation, Bruker Corporation, Human Metabolome Technologies, Inc., Metabolon Inc., LECO Corporation, and Shimadzu Corporation among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, contributing to the growth of the global metabolomics market.

For instance,

  • In June 2021, Bruker Corporation launched the FluoroType SARS-CoV-2 varied Q assay, a quantitative Liquid Array mid-plexPCR panel. This novel assay panel also detects several important mutations, enabling laboratories and hospitals to differentiate many major viral variants routinely on all positive samples. The assay achieved a sensitivity of 98% and a specificity of 100% during its clinical performance evaluation study.
  • In June 2021, at Bruker's virtual 4D-Proteomics eXceed Symposium (eXceed Symposia 2021 | Bruker), Bruker Corporation launched the two new Tim stop instruments. In addition, they advance and enable new applications and methods in unbiased proteomics/PTM characterization and unbiased, deep multi-omic biomarker discovery, for example, in cancer liquid biopsy research.

Thermo Fisher Scientific Inc

Overview:

Thermo Fisher Scientific Inc. is an American company founded in 1956 and headquartered in the United States. It provides solutions including chromatographic separations such as GC, LC and IC. It produces novel, stringent and reproducible results for high-impact discoveries.

Treatment type Portfolio:

Orbitrap Exploris GC 240: Thermo Scientific Orbitrap Exploris GC 240 mass spectrometer facilitates the most difficult analytical challenges. It delivers uncompromising qualitative and quantitative information and provides the need for research laboratories for compound identification and quantitation, including discovery profiling, metabolomics, industry research and applied quantification analyses, to gain unparalleled access to information-rich data with ease.

The global metabolomics market report would provide access to approximately 60+ market data tables, 55+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements
      • 4.1.1.2. Rising demand for metabolomics therapy
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of metabolomics instruments
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product and Services

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 7.1.2. Market Attractiveness Index, By Product and Services
  • 7.2. Separation Techniques*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Chromatography
    • 7.2.4. Liquid Chromatography
    • 7.2.5. Gas Chromatography
    • 7.2.6. Capillary Electrophoresis
  • 7.3. Detection Techniques
    • 7.3.1. Nuclear Magnetic Resonance Spectroscopy
    • 7.3.2. Mass Spectrometry
    • 7.3.3. Others
  • 7.4. Bioinformatics Tools and Services

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Nutrigenomics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biomarker & Drug Discovery
  • 8.4. Toxicology Testing
  • 8.5. Personalized Medicine
  • 8.6. Others

9. By Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.1.2. Market Attractiveness Index, By Indication
  • 9.2. Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Neurological Disorders
  • 9.4. Inborn Errors of Metabolism
  • 9.5. Cardiovascular Disorders
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Thermo Fisher Scientific Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bio-Rad Laboratories
  • 12.3. Agilent Technologies Inc.
  • 12.4. Danaher Corporation
  • 12.5. Waters Corporation
  • 12.6. Bruker Corporation
  • 12.7. Human Metabolome Technologies, Inc.
  • 12.8. Metabolon Inc.
  • 12.9. LECO Corporation
  • 12.10. Shimadzu Corporation

LIST NOT EXHAUSTIVE

13. Global Metabolomics market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us